Setup

Mineralys Therapeutics (MLYS) has one asset: lorundrostat, an aldosterone synthase inhibitor for resistant/uncontrolled hypertension. PDUFA December 22, 2026. The Q1 2026 earnings call (May 6) disclosed nothing surprising. The interesting question is whether the price level — 15-20% above our probability-weighted intrinsic estimate — reflects the actual distribution of post-approval commercial outcomes, or just the binary "approved/not approved" decision.

What the call said

• CEO framed launch as "6-7 months in advance of potential approval for lorundrostat" — management treats AstraZeneca's competing baxdrostat approval as imminent (AZ PDUFA Q2 2026, expected within weeks).
• Commercial build is live: national account executives deployed in Q1, MSL team "in place," sales force expanding. CEO declined to disclose commercial headcount for the third consecutive call.
• Payer strategy is parity access, not preferred. CCO explicit: "having parity access is something that's a focus for us."
• Partnership chicken-and-egg unchanged: partners want commercial proof; MLYS holding back hires to preserve partner optionality.
• Burn is tracking above the $120-140M annual guidance. Q1 net loss $39.3M annualizes to $157M. G&A $21M in one quarter — versus $38.6M for all of 2025.
• Cash $646M; runway reaffirmed into 2028.

What the market thinks

• Sell-side mean target $48.50 (+78% implied) — broadly bullish on approval.
• Short interest 12.6%, 7.3 days to cover — bears positioned for the downside tail.
• ATM implied vol 83% with IV rank at the 23rd percentile — vol cheap by MLYS's own history.
• Reverse call skew observed (+4.8%) in the Dec 18 chain — atypical; suggests upside-tail hedging premium.
• CEO Form 4 sales totaling ≈$2.4M in March-April 2026 (codes unverified; could be programmed 10b5-1 or discretionary).

Probability-weighted intrinsic

Our factor scenario (asi-hypertension-class):

Forward expected return at $27 is -9.6% over 365 days. Sharpe -0.23 on a long position.

Why the gap exists

Sell-side targets anchor on approval probability (≈72% per our prior) and project a multiple expansion conditional on approval. They don't model the distribution of post-approval commercial outcomes. The most likely state is AZ first, MLYS second-in-class with parity (not preferred) formulary access — partial commercial success, not blockbuster. Conditional terminal mkt cap there is ≈$1.6B, or roughly $22/share.

The reverse call skew in the Dec chain suggests some desks are positioned for the binary tails. The cross-ticker read from AZ's Q1 call ("excited to launch soon") confirms baxdrostat is weeks from approval — the resolution event whose distribution the current price level fails to reflect.

Scenarios (ranked by stock impact)

1. MLYS first-in-class (≈10%) — AZ baxdrostat CRL; collapses scenario; +50 to +130%.
2. MLYS CRL or major label restriction (≈20%) — -45 to -75%. Most actionable downside.
3. MLYS differentiates on selectivity (≈15%) — Advance-HTN cardiologist data + 374:1 selectivity drives share; +15 to +45%.
4. Class failure (≈5%) — both drugs fail; -55 to -80%.
5. Base case — MLYS second-in-class (≈50%) — -10 to -25%.

Catalysts

• AZ baxdrostat PDUFA — Q2 2026, within weeks (we estimate ≈85% approval by July 31)
• MLYS Q2 2026 earnings — August 2026; watch for commercial headcount and partnership disclosures
• MLYS PDUFA — December 22, 2026 (we estimate ≈72% approval)
• 120-day safety milestone — silent passage or leaks may reweight the CRL state

What would change our mind

• AZ baxdrostat CRL — collapses factor scenario to MLYS-first-in-class state; re-evaluate long position
• Partnership 8-K (Item 1.01) — breaks chicken-and-egg; commercial path validated
• CEO/CCO Form 4 code P (open market buy) post-AZ readout — invalidates derisking interpretation
• AdCom announcement or FDA information request — CRL state reweights higher
• 2026 burn materially above $140M — capital intensity becomes dilution risk

We're waiting for the AZ baxdrostat outcome to collapse the scenario distribution before reassessing.

Evidence